Solid Tumors Clinical Trial
Official title:
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
Verified date | March 2016 |
Source | CellabMED |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard therapy.
Status | Completed |
Enrollment | 39 |
Est. completion date | July 4, 2018 |
Est. primary completion date | July 4, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female patients aged 19 years or older 2. Patients with pathologically or cytologically confirmed advanced solid tumor which is refractory to standard treatment or for which there is no standard therapy 3. ECOG performance status = 2 4. Life expectancy of = 12 weeks 5. Adequate hematologic, hepatic and renal functions as follows: - ANC = 1,500/µL (without G-CSF support within 2 weeks before IP administration) - Platelet = 100,000/µL (without transfusion within 2 weeks before IP administration) - Hemoglobin = 10.0 g/dL (without transfusion within 4 weeks before IP administration) - Serum creatinine = 1.5 mg/dL or eGRF = 60 mL/min/1.73 m2 - AST and ALT = 2.5 x ULN (AST and ALT = 5 x ULN in the presence of liver metastasis or hepatocarcinoma) - Total bilirubin = 1.5 x ULN (with exception of the case associated with Gilbert's syndrome) - PT and aPTT = 1.5 x ULN - UPC < 1.0 (g/g) (requiring if protein = 1 positive (+) in urinalysis) 6. Patients who voluntarily give written informed consent Exclusion Criteria: 1. Patients with hematologic malignancies including lymphoma 2. Chemo-, radio-chemo-, biologic-, immuno- or radiotherapy for advanced solid tumor within 4 weeks (or nitrosoureas, mitomycin within 6 weeks or targeted biological antibody within 8 weeks) before IP administration 3. Patients had received high-dose chemotherapy requiring hematopoietic progenitor cell support within 2 years before IP administration 4. Patients with symptomatic central nervous system (CNS) metastasis (patients who are radiologically and neurologically stable condition for = 4 weeks and discontinued corticosteroids at least 4 week before IP administration are able to participate in this trial.) 5. History of deep vein thrombosis or pulmonary embolism within 1 year; Cytomegalovirus (CMV), Epstein-Barr virus (EBV), acute coronary syndrome (including unstable angina or myocardial infarction), or clinically significant cerebrovascular disease (including stroke) within 6 month; Major surgery requiring general anesthesia or respiratory assist within 4 weeks (or video-assisted thoracoscopic surgery or open-and-closed surgery within 2 weeks) before IP administration 6. Concurrent NYHA class III or IV heart failure, uncontrolled hypertension, poorly controlled arrhythmia, other clinically significant cardiovascular abnormalities at investigator's discretion (e.g. LVEF < 50%, clinical significant abnormalities of heart wall, or cardiac muscle damage), known positive result for HIV or other uncontrolled active infection disease 7. Requirement for continuous non-steroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids 8. Receiving anticoagulant, history of bleeding diathesis, massive hemoptysis, gastrointestinal hemorrhage, or peptic ulcer disease (< 325 mg aspirin is acceptable) 9. History of severe drug hypersensitivity or hypersensitivity to IP or similar Mab 10. Pregnancy or breast-feeding 11. Women of childbearing potential (WOCBP) or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment 12. Patients who received investigational product or investigational device in other clinical trials within 3weeks prior to participation in this trial 13. Patients who cannot participate in this trial at the investigator's discretion |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
CellabMED |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Serum HGF Concentration profile according to YYB101 dosing | By 12 months after enrollment of the last subject | ||
Other | Tissue cMET expression level before YYB101 dosing | Tissue cMET expression level and efficacy (Best overall response, Progress-free survival, Disease control rate) | By 12 months after enrollment of the last subject | |
Primary | Dose-escalation cohort: DLTs and MTD | 28 days | ||
Secondary | Incidence of AEs that result in discontinuation and dose reduction of YYB101 | By 12 months after enrollment of the last subject | ||
Secondary | Clinical laboratory abnormalities that result in discontinuation and dose reduction of YYB101 | By 12 months after enrollment of the last subject | ||
Secondary | Vital sign that result in discontinuation and dose reduction of YYB101 | By 12 months after enrollment of the last subject | ||
Secondary | Anti-YYB101 antibody that result in discontinuation and dose reduction of YYB101 | By 12 months after enrollment of the last subject | ||
Secondary | Area under the plasma concentration versus time curve (AUC) of YYB101 | By 4 and 8 weeks after last administration, average 16 weeks | ||
Secondary | Peak Plasma Concentration (Cmax) of YYB101 | By 4 and 8 weeks after last administration, average 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |